Fifth Circuit Affirms Government Dismissal of Cases Brought by Corporate Whistleblower

The government’s most drastic power is its ability to dismiss the case entirely.

Recently, a three-judge panel of the U.S. Court of Appeals for the Fifth Circuit sided with the government in its bid to dismiss a whistleblower case brought by a limited liability company against pharmaceutical giants Eli Lilly and Bayer.

The case offers another example of the government flexing its dismissal power in the wake of the Granston Memo, a 2018 Department of Justice directive to winnow False Claims Act cases that don’t align with government priorities. It also reflects the government’s skepticism of certain “professional” whistleblowers, offering guidance for the would-be corporate whistleblower. 

The Government’s Dismissal Power Under the False Claims Act

The False Claims Act’s qui tam provision allows private parties, known as relators, to sue on behalf of the United States when the government has been defrauded. Although the point of the statute is to empower citizens to assist the government’s fraud-fighting efforts, the government maintains significant control over the scope of that assistance. For example, if the government opts to join a relator’s lawsuit, the government assumes the “primary responsibility” for prosecuting the case, can seek to limit the relator’s participation in it, and can even settle the case over the relator’s objections. Even when the government doesn’t join the lawsuit and the relator goes it alone, the government nonetheless can seek to stay the case and overrule any dismissal sought by the relator, among other interventions. 

But the government’s most drastic power is its ability to dismiss the case entirely. The circuit courts are split on what the government must show to dismiss a case. The D.C. Circuit says the government has “unfettered discretion” to dismiss cases, while the Ninth and Tenth circuits have required the government to at least offer a valid government purpose served by the dismissal. The Seventh Circuit recently weighed in with a standard approximating unfettered discretion. Regardless of the test used, the outcome is generally the same: if the government wants the case thrown out, a court will agree to toss it. 

The government’s dismissal power received renewed attention when the Granston Memo was issued setting forth guidelines for when the government should move to nix a relator’s case. It specifically called out cases that lack merit or otherwise interfere with federal policies. In the three years following the memo’s issuance, federal courts granted 25 government motions to dismiss – up from six motions in the two years preceding the memo. 

The Fifth Circuit’s Decision and The “Professional” Relator

A decent portion of those recently dismissed cases were brought by “shell companies” established by National Health Care Analysis Group (NHCA), which is itself a partnership comprised of several limited liability companies set up by investors. The Fifth Circuit’s recent decision addressed two of those lawsuits brought by relator Health Choice Group, LLC, an NHCA shell company, against Eli Lilly and Bayer. In each case, Health Choice alleged that the pharmaceutical companies violated the Anti-Kickback Statute by offering perks to providers for prescribing their drugs. According to Health Choice, the perks included assistance with insurance billing and free nurse visits for patients to teach them how to use defendants’ drugs. 

Nearly a year after declining to intervene in the lawsuits, the government successfully moved to dismiss them. The Fifth Circuit affirmed on appeal, declining to actually adopt a standard for government dismissals, but nonetheless concluding that the dismissals served legitimate governmental purposes. Specifically, the court explained that the government had properly concluded that the costs of continued litigation outweighed any potential benefit from the lawsuits. Perhaps more notably, the court also approved of the government’s determination that the allegedly unlawful practices were “not only beneficial, but also lawful.” Federal healthcare programs, the government argued, were served, not harmed, when pharmaceutical companies provided patients “with greater access to product education and support.”

While not emphasized by the Fifth Circuit, the government made plain that it had limited patience for NHCA, an entity it deemed a “professional relator” that had filed 11 qui tam actions in courts across the country, levying nearly identical allegations against various pharmaceutical companies. The government specifically disapproved of NHCA’s investigatory methods. To develop their allegations, NHCA interviewed current and former employees of the defendants under the auspices of conducting an unbiased “research study” – not developing allegations for qui tam lawsuits. The government openly disapproved of the “false pretenses” used by NHCA to gather the lawsuits’ foundational information.

What This Means for Corporate Whistleblowers

But the government’s decision to nix the NHCA cases and the deference given to that choice by the Fifth Circuit shouldn’t be a death knell for the corporate whistleblower. In an historic first, just last month the Justice Department intervened in a lawsuit brought by the data analysis firm Integra Med Analytics

Integra Med filed a qui tam complaint against a group of nursing homes in New York, alleging improper inflation of Resource Utilization Groups, or RUGs, the system nursing homes use to measure the complexity of care required by a patient (and that Medicare, in turn, uses to reimburse nursing homes for that care). Integra Med undertook a sophisticated analysis of Medicare claims data to determine that certain nursing homes had abnormally high levels of the most severe (and most expensive) RUG scores. It then used statistical modelling to rule out innocent explanations for these anomalies. The government spent several years investigating Integra’s data-driven complaint and filed a complaint-in-intervention laying out complementary allegations of the defendant nursing homes’ knowledge of the RUG fraud. 

In contrast to the Integra Med complaint, which is a tour-de-force of statistical analysis, NHCA’s complaints lead with the fruits of the information gathered form witness interviews conducted under “false pretenses,” and are followed by a relatively simple analysis of claims data showing that providers did, in fact, prescribe defendants’ drugs. NHCA also took a blunderbuss approach, targeting a panoply of pharmaceutical industry actors engaged in similar marketing practices. 

The bottom line is that while NHCA’s business model is to ferret out fraud through data analysis, its cases against Bayer, Eli Lily, and other big pharma companies simply were not data-driven. Corporate whistleblowers – perhaps even NHCA – can expect to have greater success with the government when their allegations are driven by precise data analyses aimed at specific bad actors. 

Print Friendly, PDF & Email

Mary Inman, Esq.

Mary Inman is a partner and co-founder of Whistleblower Partners LLP, a law firm dedicated to representing whistleblowers under the various U.S. whistleblower reward programs. Mary and her colleagues have pioneered a series of successful whistleblower cases against prominent health insurers, hospitals, provider groups, and vendors under the False Claims Act alleging manipulation of the risk scores of Medicare Advantage patients. Mary is a recognized expert and frequent author, commentator, and speaker on frauds in the healthcare industry, particularly those exposed by whistleblowers. Mary is a member of the RACmonitor editorial board and a popular panelist on Monitor Monday.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

The Inpatient Admission Order: Master the Who, When, and How

The Inpatient Admission Order: Master the Who, When, and How

During this webcast Dr. Ronald Hirsch delves into the inpatient admission order process including when to get it, when it becomes effective, its impact on billing and payment, who can write it, how to cancel it, the effects on the beneficiary, and more. You’ll leave with a clear understanding of inpatient orders and guidelines for handling improper orders that you can implement immediately.

June 20, 2024
Navigating AI in Healthcare Revenue Cycle: Maximizing Efficiency, Minimizing Risks

Navigating AI in Healthcare Revenue Cycle: Maximizing Efficiency, Minimizing Risks

Michelle Wieczorek explores challenges, strategies, and best practices to AI implementation and ongoing monitoring in the middle revenue cycle through real-world use cases. She addresses critical issues such as the validation of AI algorithms, the importance of human validation in machine learning, and the delineation of responsibilities between buyers and vendors.

May 21, 2024
Leveraging the CERT: A New Coding and Billing Risk Assessment Plan

Leveraging the CERT: A New Coding and Billing Risk Assessment Plan

Frank Cohen shows you how to leverage the Comprehensive Error Rate Testing Program (CERT) to create your own internal coding and billing risk assessment plan, including granular identification of risk areas and prioritizing audit tasks and functions resulting in decreased claim submission errors, reduced risk of audit-related damages, and a smoother, more efficient reimbursement process from Medicare.

April 9, 2024
2024 Observation Services Billing: How to Get It Right

2024 Observation Services Billing: How to Get It Right

Dr. Ronald Hirsch presents an essential “A to Z” review of Observation, including proper use for Medicare, Medicare Advantage, and commercial payers. He addresses the correct use of Observation in medical patients and surgical patients, and how to deal with the billing of unnecessary Observation services, professional fee billing, and more.

March 21, 2024
Comprehensive Inpatient Clinical Documentation Integrity: From Foundations to Advanced Strategies

Comprehensive Inpatient Clinical Documentation Integrity: From Foundations to Advanced Strategies

Optimize your inpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. Participants will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.

June 26, 2024
Advanced Inpatient Clinical Documentation Integrity: Harnessing Technology, Analytics, and Compliance

Advanced Inpatient Clinical Documentation Integrity: Harnessing Technology, Analytics, and Compliance

Join expert Angela Comfort, MBA, RHIA, CDIP, CCS, CCS-P., as she helps you navigate advanced inpatient CDI technologies, regulatory changes, and system interoperability. Angela will provide actionable strategies for integrating AI and predictive analytics into CDI practices, ensuring seamless system interoperability, and maintaining compliance with evolving regulations. Attendees will learn to select and implement advanced EHR systems and CDI software, leverage data analytics to enhance documentation accuracy, and stay audit-ready with the latest compliance updates. Real-world case studies and practical tools will empower you to drive continuous improvement in CDI, improve patient outcomes, and enhance organizational efficiency. Don’t miss this opportunity to advance your CDI practices and stay ahead in this dynamic field.

July 11, 2024
Foundations of Inpatient Clinical Documentation Integrity: Enhancing Accuracy and Compliance

Foundations of Inpatient Clinical Documentation Integrity: Enhancing Accuracy and Compliance

Join expert Angela Comfort, MBA, RHIA, CDIP, CCS, CCS-P, for an insightful webcast on improving inpatient clinical documentation integrity (CDI). Inaccurate documentation can lead to misdiagnosis, improper treatment, and compromised patient safety. High workloads, lack of standardized practices, and outdated EHR systems contribute to these issues, affecting care quality and financial outcomes. Angela will offer practical strategies and tools to enhance accuracy, consistency, and timeliness in documentation. Attendees will learn to use standardized templates, checklists, and advanced EHR systems, while staying compliant with regulations. Improve patient care, ensure accurate billing, and reduce audit risks with actionable insights from this essential webcast.

June 26, 2024
Mastering E/M Coding: Navigating the Evolving Landscape

Mastering E/M Coding: Navigating the Evolving Landscape

Join industry expert, Kathy Pride, RHIT, CPC, CPMA, CCS-P, for an in-depth exploration of Evaluation and Management (E/M) coding, tailored for healthcare professionals navigating recent guideline changes. Dive into advanced topics beyond mere code selection, including shared visits, criteria for selecting E/M levels, and documentation best practices. Gain clarity on complex guideline terminology and ensure compliance with regulatory standards. This comprehensive session is essential for coders, auditors, educators, and practitioners seeking to enhance their proficiency in E/M coding and maximize revenue capture.

June 19, 2024

Trending News

Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →

Honor Memorial Day with Savings! Get 20% off all items using code MEMORIAL24 at checkout. Shop today and save! Offer valid until May 31. Exclusions apply.

Happy World Health Day! Our exclusive webcast, ‘2024 SDoH Update: Navigating Coding and Screening Assessment,’  is just $99 for a limited time! Use code WorldHealth24 at checkout.